Flu-Amp Uses

Is this medication very expensive?

 No   Yes 

• Flu-Amp indications
• Flu-Amp interactions
• Flu-Amp side effects
• Flu-Amp contraindications

Flu-Amp indications

UNASYN is indicated for the treatment of infections due to susceptible strains of the designated

microorganisms in the conditions listed below.

Skin and Skin Structure Infections caused by beta-lactamase producing strains of

Staphylococcus aureus, Escherichia coli, Klebsiella spp. (including K. pneumoniae), Proteus

mirabilis, Bacteroides fragilis, Enterobacter spp., and Acinetobacter calcoaceticus.

Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli,

Klebsiella spp. (including K. pneumoniae), Bacteroides spp. (including B. fragilis), and

Enterobacter spp.

Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, and

Bacteroides spp. (including B. fragilis).

Efficacy for this organism in this organ system was studied in fewer than 10 infections.

While UNASYN is indicated only for the conditions listed above, infections caused by

Ampicillin (Flu-Amp)-susceptible organisms are also amenable to treatment with UNASYN due to its

Ampicillin (Flu-Amp) content. Therefore, mixed infections caused by Ampicillin (Flu-Amp)-susceptible organisms and

beta-lactamase producing organisms susceptible to UNASYN should not require the addition of

another antibiotic.

Appropriate culture and susceptibility tests should be performed before treatment in order to

isolate and identify the organisms causing infection and to determine their susceptibility to

UNASYN.

Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility

studies, when there is reason to believe the infection may involve any of the beta-lactamase

producing organisms listed above in the indicated organ systems. Once the results are known,

therapy should be adjusted if appropriate.

To reduce the development of drug-resistant bacteria and maintain effectiveness of UNASYN

and other antibacterial drugs, UNASYN should be used only to treat or prevent infections that are

proven or strongly suspected to be caused by susceptible bacteria. When culture and

susceptibility information are available, they should be considered in selecting or modifying

antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns

may contribute to the empiric selection of therapy.

Flu-Amp interactions

Probenecid decreases the renal tubular secretion of Ampicillin (Flu-Amp) and

sulbactam. Concurrent use of probenecid with UNASYN may result in increased and prolonged

blood levels of Ampicillin (Flu-Amp) and sulbactam. The concurrent administration of allopurinol and

Ampicillin (Flu-Amp) increases substantially the incidence of rashes in patients receiving both drugs as

compared to patients receiving Ampicillin (Flu-Amp) alone. It is not known whether this potentiation of

Ampicillin (Flu-Amp) rashes is due to allopurinol or the hyperuricemia present in these patients. There are no

data with UNASYN and allopurinol administered concurrently. UNASYN and aminoglycosides

should not be reconstituted together due to the in vitro inactivation of aminoglycosides by the

Ampicillin (Flu-Amp) component of UNASYN.

Flu-Amp side effects

Adult Patients: UNASYN is generally well tolerated. The following adverse reactions have been

reported.

Local Adverse Reactions

Pain at IM injection site – 16%

Pain at IV injection site – 3%

Thrombophlebitis – 3%

Systemic Adverse Reactions

The most frequently reported adverse reactions were diarrhea in 3% of the patients and rash in

less than 2% of the patients.

Additional systemic reactions reported in less than 1% of the patients were: itching, nausea,

vomiting, candidiasis, fatigue, malaise, headache, chest pain, flatulence, abdominal distension,

glossitis, urine retention, dysuria, edema, facial swelling, erythema, chills, tightness in throat,

substernal pain, epistaxis and mucosal bleeding.

Pediatric Patients: Available safety data for pediatric patients treated with UNASYN

demonstrate a similar adverse events profile to those observed in adult patients. Additionally,

atypical lymphocytosis has been observed in one pediatric patient receiving UNASYN.

Adverse Laboratory Changes

Adverse laboratory changes without regard to drug relationship that were reported during clinical

trials were:

Hepatic: Increased AST (SGOT), ALT (SGPT), alkaline phosphatase, and LDH.

Hematologic: Decreased hemoglobin, hematocrit, RBC, WBC, neutrophils, lymphocytes,

platelets and increased lymphocytes, monocytes, basophils, eosinophils, and platelets.

Blood Chemistry: Decreased serum albumin and total proteins.

Renal: Increased BUN and creatinine.

Urinalysis: Presence of RBC

Flu-Amp contraindications

This medicine is not given to individuals who have previous Penicillin or cephalosporin allergy and should be used with caution in individuals with histories of significant allergies and/or asthma.

Active ingredient matches for Flu-Amp:

Ampicillin/Flucloxacillin in United Kingdom.

Ampicillin trihydrate/flucloxacillin sodium in United Kingdom.

References

1. DailyMed. "AMPICILLIN SODIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. PubChem. "ampicillin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
3. PubChem. "Flucloxacillin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).

Reviews

User reports

Consumer reviews

Information checked by Dr. Sachin Kumar, MD Pharmacology